Search

Your search keyword '"Friedman, Robb S."' showing total 13 results
Start Over Author "Friedman, Robb S."
13 results on '"Friedman, Robb S."'

1. Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Author

Yee, Andrew J., Laubach, Jacob P., Campagnaro, Erica L., Lipe, Brea C., Nadeem, Omar, Friedman, Robb S., Cole, Craig E., O’Donnell, Elizabeth K., Bianchi, Giada, Branagan, Andrew R., Schlossman, Robert L., Shapiro, Samantha J., Harrington, Cynthia C., Burke, Jill N., Gammon, Marilyn T., Lively, Kathleen J., Reimonn, Cassandra A., Andrade, Danielle X., Redd, Robert, Lohr, Jens G., Anderson, Kenneth C., Richardson, Paul G., and Raje, Noopur S.

Published
2025
Full Text
View/download PDF

2. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP

Author

Nemec, Ronald, primary, Scherrer-Crosbie, Marielle, additional, Abramson, Jeremy S., additional, Redd, Robert, additional, Gilman, Hannah K., additional, Ho, Terry, additional, Wu, Jessica, additional, Heemelaar, Julius, additional, Neuberg, Donna, additional, Hochberg, Ephraim P., additional, Barnes, Jeffrey A., additional, Armand, Philippe, additional, Jacobsen, Eric D., additional, Jacobson, Caron A., additional, Kim, Austin I., additional, Friedman, Robb S., additional, LaCasce, Ann S., additional, Neilan, Tomas G., additional, and Soumerai, Jacob D., additional

Published
2024
Full Text
View/download PDF

4. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

Author

Neilan, Tomas G., primary, Quinaglia, Thiago, additional, Onoue, Takeshi, additional, Mahmood, Syed S., additional, Drobni, Zsofia D., additional, Gilman, Hannah K., additional, Smith, Amanda, additional, Heemelaar, Julius C., additional, Brahmbhatt, Priya, additional, Ho, Jor Sam, additional, Sama, Supraja, additional, Svoboda, Jakub, additional, Neuberg, Donna S., additional, Abramson, Jeremy S., additional, Hochberg, Ephraim P., additional, Barnes, Jefferey A., additional, Armand, Philippe, additional, Jacobsen, Eric D., additional, Jacobson, Caron A., additional, Kim, Austin I., additional, Soumerai, Jacob D., additional, Han, Yuchi, additional, Friedman, Robb S., additional, Lacasce, Ann S., additional, Ky, Bonnie, additional, Landsburg, Dan, additional, Nasta, Sunita, additional, Kwong, Raymond Y., additional, Jerosch-Herold, Michael, additional, Redd, Robert A., additional, Hua, Lanqi, additional, Januzzi, James L., additional, Asnani, Aarti, additional, Mousavi, Negareh, additional, and Scherrer-Crosbie, Marielle, additional

Published
2023
Full Text
View/download PDF

5. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

Author

Kasbekar, Monica, primary, Nardi, Valentina, primary, Dal Cin, Paola, primary, Brunner, Andrew M., primary, Burke, Meghan, primary, Chen, Yi-Bin, primary, Connolly, Christine, primary, Fathi, Amir T., primary, Foster, Julia, primary, Macrae, Molly, primary, McAfee, Steven L., primary, McGregor, Kristin, primary, Narayan, Rupa, primary, Ramos, Aura Y., primary, Som, Tina T., primary, Vartanian, Meghan, primary, Friedman, Robb S., primary, Benhadji, Karim A., primary, and Hobbs, Gabriela S., primary

Published
2020
Full Text
View/download PDF

7. Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Author

Kasbekar, Monica, primary, Nardi, Valentina, additional, Dal Cin, Paola, additional, Brunner, Andrew M., additional, Chen, Yi-Bin, additional, Connolly, Christine, additional, Fathi, Amir T., additional, Foster, Julia, additional, Macrae, Molly, additional, McAfee, Steven L, additional, McGregor, Kristin, additional, Narayan, Rupa, additional, Ramos, Aura Y., additional, Som, Tina T., additional, Vartanian, Megan, additional, Friedman, Robb S, additional, Benhadji, Karim, additional, and Hobbs, Gabriela S., additional

Published
2019
Full Text
View/download PDF

8. A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Author

Yee, Andrew J., primary, Laubach, Jacob P., additional, Campagnaro, Erica L., additional, Lipe, Brea C., additional, Nadeem, Omar, additional, Friedman, Robb S, additional, Cole, Craig E., additional, O'Donnell, Elizabeth K., additional, Bianchi, Giada, additional, Branagan, Andrew R., additional, Shapiro, Samantha J., additional, Harrington, Cynthia C., additional, Burke, Jill N., additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Thorburn, Cassandra A., additional, Mann, Mason L., additional, Lohr, Jens G., additional, Anderson, Kenneth C., additional, Richardson, Paul G., additional, and Raje, Noopur S., additional

Published
2019
Full Text
View/download PDF

9. Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Author

Frede, Julia, primary, Anand, Praveen, additional, Yee, Andrew J., additional, Vijaykumar, Tushara, additional, Nair, Monica S., additional, Waldschmidt, Johannes M., additional, Potdar, Sayalee V., additional, Kloeber, Jake A., additional, Kokkalis, Antonis, additional, Guo, Guangwu, additional, Shapiro, Samantha J., additional, Mann, Mason L., additional, Friedman, Robb S, additional, Lipe, Brea C., additional, Campagnaro, Erica L., additional, Cole, Craig E., additional, O'Donnell, Elizabeth K., additional, Guerrero, Thomas, additional, Nadeem, Omar, additional, Laubach, Jacob P., additional, Munshi, Nikhil C., additional, Richardson, Paul G., additional, Anderson, Kenneth C., additional, Raje, Noopur, additional, Knoechel, Birgit, additional, and Lohr, Jens G., additional

Published
2019
Full Text
View/download PDF

10. Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Author

Waldschmidt, Johannes M., primary, Yee, Andrew J., additional, Vijaykumar, Tushara, additional, Frede, Julia, additional, Anand, Praveen, additional, Potdar, Sayalee, additional, Nair, Monica S., additional, Kokkalis, Antonis, additional, Kloeber, Jake A., additional, Guo, Guangwu, additional, Shapiro, Samantha J., additional, Mann, Mason L., additional, Friedman, Robb S, additional, Lipe, Brea C., additional, Campagnaro, Erica L., additional, O'Donnell, Elizabeth K., additional, Guerrero, Thomas, additional, Laubach, Jacob P., additional, Munshi, Nikhil C., additional, Richardson, Paul G., additional, Anderson, Kenneth C., additional, Raje, Noopur S., additional, Knoechel, Birgit, additional, and Lohr, Jens G., additional

Published
2019
Full Text
View/download PDF

12. Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1Fusion: Data from an Expanded Access Program

Author

Kasbekar, Monica, Nardi, Valentina, Dal Cin, Paola, Brunner, Andrew M., Chen, Yi-Bin, Connolly, Christine, Fathi, Amir T., Foster, Julia, Macrae, Molly, McAfee, Steven L, McGregor, Kristin, Narayan, Rupa, Ramos, Aura Y., Som, Tina T., Vartanian, Megan, Friedman, Robb S, Benhadji, Karim, and Hobbs, Gabriela S.

Abstract

Introduction

Published
2019
Full Text
View/download PDF

13. Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy.

Author

Johnson PC, Abramson JS, LaCasce AS, Armand P, Barnes J, Merryman RW, Soumerai J, Hochberg E, Takvorian RW, Jacobson CA, Crombie JL, Fisher DC, Schwartz J, Friedman RS, Stacey J, Yang D, Coffey B, Markowitz N, Odejide OO, and El-Jawahri A

Abstract

Background: Aggressive non-Hodgkin lymphoma (aNHL) is more common in older adults. Although chemoimmunotherapy can yield durable remissions, it is also associated with significant toxicities. Despite this, longitudinal studies assessing patient-reported outcomes (PROs) with chemoimmunotherapy in this population are lacking., Patients and Methods: We conducted a longitudinal study of 105 adults aged ≥65 years who initiated up-front chemoimmunotherapy for aNHL across 2 academic centers and their community affiliates between September 2020 and January 2023. Quality of life (QoL) was assessed using the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym), physical symptoms via the revised Edmonton Symptom Assessment Scale (ESAS-r), and psychological symptoms with the Hospital Anxiety and Depression Scale (HADS). Assessments were performed at baseline; 6, 12, 18, and 24 weeks post-therapy initiation; and 1 year post-therapy initiation. Frailty status was evaluated at baseline using the Fondazione Italiana Linfomi geriatric assessment (GA) and the Vulnerable Elders Survey-13 (VES-13). Linear mixed models were used to examine the trajectory of PROs over time, and linear regression was employed to identify factors associated with QoL at 1 year., Results: The median patient age was 73 years (range, 64-99), with 41.9% aged ≥75 years. Most patients (53.8%) had an age-adjusted International Prognostic Index (IPI) of 2/3, and 70.5% had diffuse large B-cell lymphoma. Overall, 50.5% and 45.7% were identified as frail or vulnerable on GA and VES-13, respectively. Longitudinal QoL, physical symptoms, anxiety, and depression all significantly improved over time (all P≤.001). QoL improved regardless of age category (65-74 vs ≥75 years) or frailty status. In multivariate analyses, being married/living with partner was associated with better QoL at 1 year (β=11.6; P=.026), whereas frailty on GA (β= -9.90; P=.036) was associated with worse QoL., Conclusions: Older adults with aNHL receiving chemoimmunotherapy experienced significant and durable improvement in QoL, physical symptoms, and psychological health up to 1 year post-therapy initiation, irrespective of age or frailty status. However, frailty was associated with worse QoL at 1 year post-therapy initiation. These findings underscore the importance of integrating GAs into treatment planning for older adults with aNHL.

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results